Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infections in combination with other antiretroviral agents. Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
- Mechanism
- Curator reviewed
Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1). It directly binds reverse transcriptase and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma.
- Primary indication
- Etravirine is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in treatment-experienced patients ≥2 years of age.Curator reviewed · 1 structured indication
- Formula / weight
- C20H15BrN6O · 435.277 g/mol (avg)
- First approval
- Canada, 2008 · United States, 2008 · European Union, 2016
- Code names
- R-165335 · TMC-125
- Brand names
Resolves to
PYGWGZALEOIKDF-UHFFFAOYSA-NSMILESCC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#NWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Etravirine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account